You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Noninvasive Platform to Assess Maternal Risk for Perinatal Complications in the First Trimester
SBC: Cradle Genomics, Inc. Topic: NICHDLimited information is available about early human placentation when many pregnancy pathologies originateTo address this knowledge gap and begin development of robust diagnostic tool to manage pregnancy complicationswe propose a pilot study based on a highly sensitive immune assay and our company s base technologyTrophoblast Retrieval and Isolation from the CervixTRICTRIC uses a Pap smearconsidere ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss
SBC: NANOMEDIC INC Topic: NIAAbstractIn this SBIR Phase I applicationour goal is to demonstrate proof of concept of our lead chelating agent as a potential therapeutic for the prevention of osteoporosis induced by aromatase inhibitorAItherapy in postmenopausal women with hormone receptor positive breast cancerAlthough AI therapy shows great improvements in cancer free and overall survivalits treated patients face a risk of os ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
High-throughput nanoMEA-based Proarrhythmia Assay
SBC: CURI BIO, INC. Topic: NHLBIPROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Daily and localized NSAID sonophoresis for symptomatic treatment of knee osteoarthritis
SBC: ZETROZ SYSTEMS LLC Topic: NIAProject SummaryOsteoarthritisOAis the most common type of arthritisaffecting overmillion adults in the United States inand represents overof medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of HealthOverof individuals overhave symptomatic OA and reduced mobility due to the diseaseOA pain is often mitigated with conservative treatment app ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines
SBC: HDT BIO CORP Topic: NCIRDProject Summary SignificanceSinceavian influenza AH Nhas sickened overpeople with amortality rateHalf of all cases occurred inwhich also saw the emergence of a highly pathogenic strainThusH Navian influenza is poised to emerge as a devastating pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccineswhether attenuatedinactivatedsplit or recombinantare insufficiently imm ...
SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Visible light activated implant devices to prevent biofilm formation
SBC: Sonata LLC Topic: NCEZIDPrevention of biofilms on invasive medical devices has the potential to significantly reduce hospital acquired infections and improve patient outcomesProsthetic joint infectionsPJIsacquired from orthopedic implantsoften the result of microorganism contamination on the implant surface during surgeryaffect patient recoveries and can lead to significant mortalitiesOne approach for reducing the incide ...
SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction
SBC: Recursion Pharmaceuticals, LLC Topic: NIADESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The pla ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Synthetic Universal Flu Vaccine
SBC: TRIA BIOSCIENCE CORP. Topic: NCIRDAbstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confronting the global Influenza marketVirus diversity and mutation rates necessitate the annual production of hundreds of millions of vaccines using antiquated egg based technologiesCompounding this is th ...
SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Establishing the POROS Intracellular Delivery System as a Platform for Cellular Therapeutics
SBC: OPENCELL TECHNOLOGIES, INC. Topic: 100Abstract SignificanceIntracellular delivery of nucleic acids to immune cells is an important component of many current and anticipated cellular therapiesincluding chimeric antigen receptor T CellCAR Ttherapies for the treatment of cancerThese therapies use immune cells called T cellseither from the patient themselvesor a healthy donorand genetically engineer them to kill the tumor cellsThe genetic ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance
SBC: ISOPLEXIS CORPORATION Topic: 102Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health